CN113993520A - 血管性水肿的治疗 - Google Patents

血管性水肿的治疗 Download PDF

Info

Publication number
CN113993520A
CN113993520A CN202080043658.4A CN202080043658A CN113993520A CN 113993520 A CN113993520 A CN 113993520A CN 202080043658 A CN202080043658 A CN 202080043658A CN 113993520 A CN113993520 A CN 113993520A
Authority
CN
China
Prior art keywords
compound
formula
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080043658.4A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·保罗·费尼尔
萨利·路易斯·马什
安德烈亚斯·梅茨尔
迈克尔·戴维·史密斯
克里斯多夫·马丁·叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Priority to CN202410143627.6A priority Critical patent/CN118078821A/zh
Publication of CN113993520A publication Critical patent/CN113993520A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN202080043658.4A 2019-06-14 2020-06-15 血管性水肿的治疗 Pending CN113993520A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410143627.6A CN118078821A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
US62/861,758 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
GB1910125.2 2019-07-15
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410143627.6A Division CN118078821A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗

Publications (1)

Publication Number Publication Date
CN113993520A true CN113993520A (zh) 2022-01-28

Family

ID=67700187

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080043658.4A Pending CN113993520A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗
CN202410143627.6A Pending CN118078821A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410143627.6A Pending CN118078821A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗

Country Status (18)

Country Link
US (1) US20220226293A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982961A1 (cg-RX-API-DMAC7.html)
JP (1) JP7640474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024221A (cg-RX-API-DMAC7.html)
CN (2) CN113993520A (cg-RX-API-DMAC7.html)
AR (1) AR119159A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020293616A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142220A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003243A1 (cg-RX-API-DMAC7.html)
GB (1) GB201910125D0 (cg-RX-API-DMAC7.html)
IL (1) IL288612A (cg-RX-API-DMAC7.html)
MA (1) MA56188A (cg-RX-API-DMAC7.html)
MX (1) MX2021014558A (cg-RX-API-DMAC7.html)
PH (1) PH12021552967A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113375PA (cg-RX-API-DMAC7.html)
TW (1) TW202112371A (cg-RX-API-DMAC7.html)
WO (1) WO2020249979A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003386A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108576A (zh) * 2014-11-27 2017-08-29 卡尔维斯塔制药有限公司 作为血浆激肽释放酶抑制剂的n‑((杂)芳基甲基)‑杂芳基‑甲酰胺化合物
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
PL3716952T3 (pl) * 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108576A (zh) * 2014-11-27 2017-08-29 卡尔维斯塔制药有限公司 作为血浆激肽释放酶抑制剂的n‑((杂)芳基甲基)‑杂芳基‑甲酰胺化合物
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M CICARDI等: "DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema" *
MIGNON VAN DEN ELZEN等: "Efficacy of Treatment of Non-hereditary Angioedema" *
NISHA S. PATEL等: "Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003386A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Also Published As

Publication number Publication date
GB201910125D0 (en) 2019-08-28
JP7640474B2 (ja) 2025-03-05
CA3142220A1 (en) 2020-12-17
SG11202113375PA (en) 2021-12-30
MA56188A (fr) 2022-04-20
CL2023000699A1 (es) 2023-10-30
AR119159A1 (es) 2021-12-01
JP2022537913A (ja) 2022-08-31
US20220226293A1 (en) 2022-07-21
BR112021024447A2 (pt) 2022-01-18
PH12021552967A1 (en) 2022-07-25
AU2020293616A1 (en) 2022-01-27
MX2021014558A (es) 2022-04-06
CN118078821A (zh) 2024-05-28
TW202112371A (zh) 2021-04-01
EP3982961A1 (en) 2022-04-20
IL288612A (en) 2022-02-01
WO2020249979A1 (en) 2020-12-17
CL2021003243A1 (es) 2022-09-30
KR20220024221A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7688078B2 (ja) 遺伝性血管性浮腫の治療
JP7640474B2 (ja) 血管性浮腫の治療
US20240122909A1 (en) Treatments of hereditary angioedema
US20230381162A1 (en) Treatments of angioedema
TW202228686A (zh) 血管性水腫之治療
HK40101443A (en) Treatments of hereditary angioedema
EA048676B1 (ru) Лечение наследственного ангионевротического отека
HK40070596A (en) Treatments of hereditary angioedema
HK40070596B (en) Treatments of hereditary angioedema
JP2022069377A (ja) 血管性浮腫の処置
EP4673437A1 (en) New solid form of a plasma kallikrein inhibitor
WO2025172692A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172693A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema
EP4448114A1 (en) Methods of treatment using lou064

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220128

RJ01 Rejection of invention patent application after publication